Review



human il19 protein  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress human il19 protein
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Human Il19 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il19 protein/product/MedChemExpress
    Average 93 stars, based on 4 article reviews
    human il19 protein - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "TOPK Drives IL19-Mediated Crosstalk Between Cancer Cells and Fibroblasts to Promote Solar UV-Induced Skin Damage and Carcinogenesis"

    Article Title: TOPK Drives IL19-Mediated Crosstalk Between Cancer Cells and Fibroblasts to Promote Solar UV-Induced Skin Damage and Carcinogenesis

    Journal: Cancers

    doi: 10.3390/cancers17132067

    TOPK drives IL19-induced cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Figure Legend Snippet: TOPK drives IL19-induced cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).

    Techniques Used: Activation Assay, Knockdown, Expressing, Western Blot, MTS Assay, Recombinant, Phospho-proteomics, Immunofluorescence, Staining, Control

    TOPK/IL19 signaling crosstalk between cSCC cells and fibroblasts. In cSCC cells, TOPK activates multiple downstream pathways, including NF-κB, PI3K, ERK, p38, JNK, PKA, PKC, and PKG, which converge to promote the transcription and secretion of IL19. TOPK also enhances the expression of NFκB and IL19 in fibroblasts. Secreted IL19 promotes cSCC cell growth and acts in a paracrine manner on nearby fibroblasts, leading to their activation, as indicated by the increased expression of αSMA and FAPα. These activated fibroblasts further support cancer cell growth, suggesting a feedforward loop that drives tumor progression through IL19-mediated communication between tumor cells and the surrounding stroma.
    Figure Legend Snippet: TOPK/IL19 signaling crosstalk between cSCC cells and fibroblasts. In cSCC cells, TOPK activates multiple downstream pathways, including NF-κB, PI3K, ERK, p38, JNK, PKA, PKC, and PKG, which converge to promote the transcription and secretion of IL19. TOPK also enhances the expression of NFκB and IL19 in fibroblasts. Secreted IL19 promotes cSCC cell growth and acts in a paracrine manner on nearby fibroblasts, leading to their activation, as indicated by the increased expression of αSMA and FAPα. These activated fibroblasts further support cancer cell growth, suggesting a feedforward loop that drives tumor progression through IL19-mediated communication between tumor cells and the surrounding stroma.

    Techniques Used: Expressing, Activation Assay



    Similar Products

    93
    MedChemExpress human il19 protein
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Human Il19 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il19 protein/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    human il19 protein - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    R&D Systems human hil 19
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Human Hil 19, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hil 19/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human hil 19 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress human il 19
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Human Il 19, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il 19/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    human il 19 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    Meso Scale Diagnostics LLC human il- 19 msd sandwich immunoassay
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Human Il 19 Msd Sandwich Immunoassay, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il- 19 msd sandwich immunoassay/product/Meso Scale Diagnostics LLC
    Average 90 stars, based on 1 article reviews
    human il- 19 msd sandwich immunoassay - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    93
    R&D Systems hil 24
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Hil 24, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hil 24/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    hil 24 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    92
    R&D Systems h3 19 6 1
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    H3 19 6 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/h3 19 6 1/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    h3 19 6 1 - by Bioz Stars, 2026-02
    92/100 stars
      Buy from Supplier

    90
    Elabscience Biotechnology quantitative human il-19 elisa kits
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Quantitative Human Il 19 Elisa Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantitative human il-19 elisa kits/product/Elabscience Biotechnology
    Average 90 stars, based on 1 article reviews
    quantitative human il-19 elisa kits - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    93
    MedChemExpress il19
    TOPK drives <t>IL19-induced</t> cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).
    Il19, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il19/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    il19 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    Image Search Results


    TOPK drives IL19-induced cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).

    Journal: Cancers

    Article Title: TOPK Drives IL19-Mediated Crosstalk Between Cancer Cells and Fibroblasts to Promote Solar UV-Induced Skin Damage and Carcinogenesis

    doi: 10.3390/cancers17132067

    Figure Lengend Snippet: TOPK drives IL19-induced cSCC growth and fibroblast activation. ( A ) Differentially expressed genes in the cytokine–cytokine receptor interaction pathway upon TOPK knockdown. The fold change and p -values of key genes are shown, with IL19 exhibiting the most significant decrease. ( B , C ) Knockdown of TOPK significantly reduced IL19 expression at the protein level and its secretion into the conditioned media (CM) of keratinocytes and cSCC cells, as determined by Western blotting. ( D ) IL19 treatment promoted cSCC A431 and SCC12 cell growth, as assessed by MTS assay. ( E ) cSCC A431 and SCC12 cells were treated with recombinant human IL19 (40 ng/mL) for 4 days. Cell growth was measured using the MTS assay. IL19 treatment significantly increased cell growth compared to untreated controls. ( F ) IL19 activated ERK, PI3K, AKT, and TOPK phosphorylation within 15 to 30 min of treatment, but this effect was not sustained at 24 h, as shown by Western blot analysis. ( G ) IL19 and αSMA expression were elevated in chronic TGFβ-treated BJ-TGFβ fibroblasts compared with normal BJ fibroblasts. ( H – K ) TOPK knockdown significantly suppressed IL19 expression and secretion in both normal BJ fibroblasts and activated BJ-TGFβ fibroblasts. ( L , M ) IL19 treatment enhanced the expression of αSMA and FAPα in normal BJ fibroblasts, as demonstrated by Western blot ( L ) and immunofluorescence staining ( M ). ( N ) The density of αSMA was obtained for each sample. Data are shown as means ± SD from three independent experiments. The asterisks indicate a significant difference compared to the group of control samples ( n = 3) (*, p < 0.05; **, p < 0.01; ***, p < 0.001 and ns: no significant difference, one-way ANOVA followed by Dunnett’s post hoc test).

    Article Snippet: Human IL19 protein (10 μg, P7212) was purchased from MedChemExpress (MCE, Princeton, NJ, USA).

    Techniques: Activation Assay, Knockdown, Expressing, Western Blot, MTS Assay, Recombinant, Phospho-proteomics, Immunofluorescence, Staining, Control

    TOPK/IL19 signaling crosstalk between cSCC cells and fibroblasts. In cSCC cells, TOPK activates multiple downstream pathways, including NF-κB, PI3K, ERK, p38, JNK, PKA, PKC, and PKG, which converge to promote the transcription and secretion of IL19. TOPK also enhances the expression of NFκB and IL19 in fibroblasts. Secreted IL19 promotes cSCC cell growth and acts in a paracrine manner on nearby fibroblasts, leading to their activation, as indicated by the increased expression of αSMA and FAPα. These activated fibroblasts further support cancer cell growth, suggesting a feedforward loop that drives tumor progression through IL19-mediated communication between tumor cells and the surrounding stroma.

    Journal: Cancers

    Article Title: TOPK Drives IL19-Mediated Crosstalk Between Cancer Cells and Fibroblasts to Promote Solar UV-Induced Skin Damage and Carcinogenesis

    doi: 10.3390/cancers17132067

    Figure Lengend Snippet: TOPK/IL19 signaling crosstalk between cSCC cells and fibroblasts. In cSCC cells, TOPK activates multiple downstream pathways, including NF-κB, PI3K, ERK, p38, JNK, PKA, PKC, and PKG, which converge to promote the transcription and secretion of IL19. TOPK also enhances the expression of NFκB and IL19 in fibroblasts. Secreted IL19 promotes cSCC cell growth and acts in a paracrine manner on nearby fibroblasts, leading to their activation, as indicated by the increased expression of αSMA and FAPα. These activated fibroblasts further support cancer cell growth, suggesting a feedforward loop that drives tumor progression through IL19-mediated communication between tumor cells and the surrounding stroma.

    Article Snippet: Human IL19 protein (10 μg, P7212) was purchased from MedChemExpress (MCE, Princeton, NJ, USA).

    Techniques: Expressing, Activation Assay